Published in Int J Neuropsychopharmacol on August 27, 2015
Nonlinear spatial normalization using basis functions. Hum Brain Mapp (1999) 9.24
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci (2007) 4.46
Multimodal image coregistration and partitioning--a unified framework. Neuroimage (1997) 4.26
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab (2001) 3.31
The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci (2006) 2.44
Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry (2006) 2.21
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord (2009) 2.17
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry (2004) 2.00
D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry (1995) 1.80
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab (2009) 1.80
Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A (1996) 1.78
An automated method for the extraction of regional data from PET images. Psychiatry Res (2006) 1.67
Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry (2004) 1.63
Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab (1995) 1.54
Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat (2009) 1.48
Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A (2006) 1.46
Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther (1992) 1.40
Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci U S A (2008) 1.39
Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci (1992) 1.30
Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry (2009) 1.25
Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem (2006) 1.20
Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry (2010) 1.20
Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience (1996) 1.18
Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab (2006) 1.10
Obtained effect size as a function of sample size in approved antidepressants: a real-world illustration in support of better trial design. Int Clin Psychopharmacol (2012) 1.04
How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry (1999) 1.03
High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry (2003) 1.01
Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry (2011) 0.98
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther (1989) 0.95
The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry (2001) 0.95
Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol (1998) 0.95
The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology (2011) 0.95
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem (2006) 0.95
Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology (2009) 0.93
Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography. JAMA Psychiatry (2014) 0.92
Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci (1992) 0.91
Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav (2003) 0.91
11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol (1997) 0.90
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology (Berl) (1998) 0.87
Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J Neurochem (2007) 0.87
In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approach. J Cereb Blood Flow Metab (2009) 0.86
Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms. Neuropsychopharmacology (2013) 0.85
Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther (1989) 0.84
Synthesis of some 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. Nucl Med Biol (1997) 0.84
Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull (1987) 0.82
Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett (2003) 0.82
Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord (1991) 0.82
General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci (2011) 0.82
On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology (2004) 0.81
Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) (2007) 0.81
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. Pharmacogenomics (2014) 0.80
Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study. J Psychiatry Neurosci (2011) 0.80
Greater monoamine oxidase a binding in alcohol dependence. Biol Psychiatry (2013) 0.78
History and therapeutic use of MAO-A inhibitors: a historical perspective of mao-a inhibitors as antidepressant drug. Curr Top Med Chem (2012) 0.76
Tolerability and efficacy of high-dose moclobemide alone and in combination with lithium and trazodone. J Clin Psychopharmacol (2000) 0.76
Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry (2004) 0.76
Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. Am J Psychiatry (2007) 0.76